• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Open Neuroendocrinology Journal >The Chemokine SDF1/CXCL12: A Novel Autocrine/Paracrine Factor Involved In Pituitary Adenoma Development
【24h】

The Chemokine SDF1/CXCL12: A Novel Autocrine/Paracrine Factor Involved In Pituitary Adenoma Development

机译：趋化因子SDF1 / CXCL12：涉及垂体腺瘤发展的新型自分泌/旁分泌因子。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The relevance of the chemokine/chemokine receptor system has broaden to several tissues. Besides their physiologicrole as chemotactic cytokines in immune surveillance, it is now clear that chemokines are key players in severalpathological processes such as inflammation, infection, and cancer. In particular the altered expression of SDF1/CXCL12and its receptor CXCR4 strongly affects cancer cell proliferation, recruitment of immunosuppressive cells,neovascularization and metastasization. CXCL12 and CXCR4 are widely expressed in central nervous system cellsincluding hypotalamus and pituitary gland. Increasing evidence supports now the hypothesis that CXCL12 acts as aneuromodulatory activity on the hypothalamus/pituitary axis and is a regulatory molecule of pituitary function. Moreover,the differential expression of CXCL12 and CXCR4 in normal and tumor pituitary adenoma cells suggests theirinvolvement in pituitary tumor development through autocrine/paracrine mechanisms leading to adenoma cellproliferation and hormone hypersecretion. Future studies focusing the pathways sustained by chemokines may helpidentify the tumor-initiating events and accordingly possible strategies may be developed targeting these pathways inhuman pituitary tumors.
机译：趋化因子/趋化因子受体系统的相关性已扩大到几个组织。除了它们在免疫监视中作为趋化性细胞因子的生理作用外，现在已经清楚趋化因子是炎症，感染和癌症等几种病理过程的关键参与者。特别地，SDF1 / CXCL12及其受体CXCR4的表达改变强烈地影响癌细胞增殖，免疫抑制细胞的募集，新生血管形成和转移。 CXCL12和CXCR4在包括下丘脑和垂体在内的中枢神经系统细胞中广泛表达。现在越来越多的证据支持以下假设：CXCL12在下丘脑/垂体轴上充当神经调节活性，并且是垂体功能的调节分子。此外，CXCL12和CXCR4在正常和肿瘤垂体腺瘤细胞中的差异表达表明它们通过自分泌/旁分泌机制参与垂体瘤的发展，导致腺瘤细胞增殖和激素过度分泌。未来研究集中于趋化因子维持的途径可能有助于鉴定肿瘤引发事件，因此可能针对人垂体肿瘤的这些途径开发可能的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号